Form 4: Avalo Therapeutics Director Converts RSUs
Insider Transaction Report
Avalo Therapeutics Director Jonathan Goldman converted 3,166 restricted stock units into common stock on March 28, 2026, as part of a routine vesting schedule.
Summary
- Jonathan Goldman, a Director of Avalo Therapeutics, Inc. (AVTX), converted 3,166 restricted stock units (RSUs) into common stock on March 28, 2026.
- The conversion was on a one-for-one basis, resulting in Goldman directly owning 3,166 shares of common stock following the transaction.
- This transaction is part of a larger grant of 9,500 restricted stock units awarded to Goldman on August 13, 2024.
- The original RSU grant vests in three equal installments: 1/3 on March 28, 2025, 1/3 on March 28, 2026, and 1/3 on March 28, 2027, contingent on Goldman's continued service.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, representing a routine vesting and conversion of equity compensation for a director, with no immediate positive or negative implications for the company's operational or financial performance.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that RSU conversions are a common form of executive and director compensation, representing the vesting of previously granted equity awards rather than a discretionary market transaction. This is a routine disclosure for insiders in publicly traded companies.
Stakeholder Impact
- Shareholders: The conversion increases the number of outstanding common shares, leading to minor dilution, which is a standard consequence of equity compensation plans.
Next Steps
- Future vesting of the remaining restricted stock units on March 28, 2027, subject to Jonathan Goldman's continued service as a Director.
Key Dates
| Date | Description |
|---|---|
| 08/13/2024 | Jonathan Goldman was granted 9,500 restricted stock units. |
| 03/28/2025 | First vesting date for 1/3 of the granted restricted stock units. |
| 03/28/2026 | Second vesting date for 1/3 of the granted restricted stock units and conversion of 3,166 RSUs into common stock. |
| 03/31/2026 | Signature date of the reporting person's attorney-in-fact for the Form 4 filing. |
| 03/28/2027 | Third vesting date for 1/3 of the granted restricted stock units. |
Recommendation
holdThe filing details a routine conversion of restricted stock units by a director, which is a standard compensation event and does not provide new information to alter an investment thesis for Avalo Therapeutics. It reflects the director's continued equity stake in the company, but does not suggest a change in fundamental value or outlook.
Keywords
Avalo Therapeutics, AVTX, Jonathan Goldman, Form 4, Restricted Stock Units, RSU conversion, insider transaction, director stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.